Hieu Nguyen, MD
Infectious Disease · Decatur, GANPI 1962455741
Payments from drug & device makers
Across 161 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$731
- Gilead$580
- AbbVie$521
- Merck$438
- Acell, Inc.$305
- Insmed, Inc.$192
- plus $1K from 26 others
What the payments were for
- Travel & lodging$932%
- Food & beverage$3,95097%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 32 | $731 |
| Gilead | 21 | $580 |
| AbbVie(2 entities) | 21 | $521 |
| Merck | 20 | $438 |
| Acell, Inc. | 3 | $305 |
| Insmed, Inc. | 8 | $192 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $171 |
| Johnson & Johnson | 10 | $144 |
| Melinta Therapeutics, LLC | 8 | $135 |
| La Jolla Pharmaceutical Company | 4 | $132 |
| Smith+Nephew | 4 | $73 |
| Janssen Scientific Affairs, LLC | 1 | $64 |
| Aimmune Therapeutics, Inc. | 3 | $57 |
| Kerecis Limited | 1 | $54 |
| Paratek Pharmaceuticals, Inc. | 2 | $49 |
| Astellas Pharma US Inc | 2 | $42 |
| Amgen(2 entities) | 2 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $39 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $32 |
| Aroa Biosurgery Incorporated | 2 | $31 |
| Averitas Pharma Inc. | 2 | $30 |
| Theratechnologies Inc. | 1 | $27 |
| Mayne Pharma Commercial LLC | 1 | $24 |
| Mylan Institutional Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $22 |
| Nabriva Therapeutics, PLC | 1 | $20 |
| Shionogi Inc | 1 | $17 |
| Vyera Pharmaceuticals, LLC | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Reapplix Inc. | 1 | $13 |
| Reprise Biomedical, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,065 in reported general payments places this provider in the 60th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vancomycin Hcl | 14 | $5,639 |
| Doxycycline Hyclate | 69 | $1,243 |
| Rifampin | 16 | $1,081 |
| Ondansetron OdtOndansetron | 21 | $429 |
| Cephalexin | 20 | $264 |
| Ciprofloxacin Hcl | 13 | $241 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $205 |
| Fluconazole | 15 | $192 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Decatur
- Robin DretlerDecatur$1.8M
- Anson WurapaDecatur$742K
- Alexandra DretlerDecatur$203K
- Vincent MarconiDecatur$20K
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Harold KatnerMacon$1.3M
- Andrew DoldDacula$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.